Nordea Investment Management AB grew its holdings in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 2.5% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 12,884,810 shares of the company’s stock after buying an additional 311,894 shares during the quarter. Teva Pharmaceutical Industries Limited accounts for approximately 1.1% of Nordea Investment Management AB’s holdings, making the stock its 28th biggest holding. Nordea Investment Management AB owned approximately 1.27% of Teva Pharmaceutical Industries Limited worth $428,033,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Bronfman E.L. Rothschild L.P. raised its position in shares of Teva Pharmaceutical Industries Limited by 7.8% during the 1st quarter. Bronfman E.L. Rothschild L.P. now owns 3,617 shares of the company’s stock valued at $116,000 after buying an additional 261 shares in the last quarter. Kistler Tiffany Companies LLC raised its position in shares of Teva Pharmaceutical Industries Limited by 74.7% during the 2nd quarter. Kistler Tiffany Companies LLC now owns 3,673 shares of the company’s stock valued at $122,000 after buying an additional 1,571 shares in the last quarter. FNY Managed Accounts LLC purchased a new stake in shares of Teva Pharmaceutical Industries Limited during the 1st quarter valued at about $123,000. Sterling Investment Advisors Ltd. raised its position in shares of Teva Pharmaceutical Industries Limited by 2.6% during the 1st quarter. Sterling Investment Advisors Ltd. now owns 3,900 shares of the company’s stock valued at $125,000 after buying an additional 100 shares in the last quarter. Finally, Cutler Capital Management LLC purchased a new stake in shares of Teva Pharmaceutical Industries Limited during the 2nd quarter valued at about $133,000. Hedge funds and other institutional investors own 56.76% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “Nordea Investment Management AB Acquires 311,894 Shares of Teva Pharmaceutical Industries Limited (TEVA)” was first reported by Daily Political and is the property of of Daily Political. If you are accessing this piece of content on another domain, it was stolen and republished in violation of international copyright & trademark legislation. The original version of this piece of content can be accessed at https://www.dailypolitical.com/2017/09/23/nordea-investment-management-ab-acquires-311894-shares-of-teva-pharmaceutical-industries-limited-teva.html.

Teva Pharmaceutical Industries Limited (NYSE TEVA) traded up 0.23% during trading on Friday, hitting $17.19. 8,986,279 shares of the stock were exchanged. Teva Pharmaceutical Industries Limited has a 12 month low of $15.22 and a 12 month high of $51.51. The stock’s market cap is $17.47 billion. The stock’s 50 day moving average price is $18.13 and its 200 day moving average price is $28.20.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) last announced its quarterly earnings data on Thursday, August 3rd. The company reported $0.99 earnings per share for the quarter, missing analysts’ consensus estimates of $1.06 by ($0.07). The business had revenue of $5.69 billion during the quarter, compared to analyst estimates of $5.72 billion. Teva Pharmaceutical Industries Limited had a negative net margin of 25.18% and a positive return on equity of 15.96%. The company’s revenue for the quarter was up 12.9% on a year-over-year basis. During the same quarter last year, the firm posted $1.25 EPS. Analysts forecast that Teva Pharmaceutical Industries Limited will post $4.32 EPS for the current fiscal year.

The firm also recently disclosed a quarterly dividend, which was paid on Thursday, September 14th. Investors of record on Tuesday, August 29th were issued a $0.085 dividend. This represents a $0.34 dividend on an annualized basis and a dividend yield of 1.98%. The ex-dividend date of this dividend was Friday, August 25th. Teva Pharmaceutical Industries Limited’s dividend payout ratio (DPR) is currently -15.36%.

Several brokerages have recently issued reports on TEVA. Royal Bank Of Canada decreased their target price on shares of Teva Pharmaceutical Industries Limited from $21.00 to $15.00 and set an “underperform” rating on the stock in a research report on Monday, September 18th. Credit Suisse Group set a $39.00 target price on shares of Teva Pharmaceutical Industries Limited and gave the company a “buy” rating in a research report on Thursday, August 3rd. Maxim Group restated a “hold” rating and set a $15.50 target price on shares of Teva Pharmaceutical Industries Limited in a research report on Thursday, September 14th. Cantor Fitzgerald set a $31.00 target price on shares of Teva Pharmaceutical Industries Limited and gave the company a “hold” rating in a research report on Thursday, June 22nd. Finally, Vetr upgraded shares of Teva Pharmaceutical Industries Limited from a “hold” rating to a “buy” rating and set a $34.17 target price on the stock in a research report on Monday, July 24th. Five research analysts have rated the stock with a sell rating, nineteen have given a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the stock. The stock currently has an average rating of “Hold” and a consensus target price of $30.91.

About Teva Pharmaceutical Industries Limited

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.

Want to see what other hedge funds are holding TEVA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Teva Pharmaceutical Industries Limited (NYSE:TEVA).

Institutional Ownership by Quarter for Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Receive News & Ratings for Teva Pharmaceutical Industries Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries Limited and related companies with MarketBeat.com's FREE daily email newsletter.